Agency Information Collection Activities; Proposed Collection; Comment Request; Biologics License Applications, Procedures and Requirements
FDA proposes to extend information collection for Biologics License Applications (BLA) procedures. This is not directly related to cosmetics or MoCRA, but may affect businesses that also handle biologics.
Aforeworn detected this change in the Cosmetics & Personal-Care (MoCRA) space on July 6, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated Low urgency. Cosmetics businesses that also manufacture or distribute biologics (e.g., certain contract manufacturers or importers). should confirm how it applies to their specific situation before acting. There is a time constraint attached: Comments due by September 4, 2026.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Cosmetics & Personal-Care (MoCRA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
FDA is seeking public comment on extending the information collection for BLA procedures and requirements.
Who it affects
Cosmetics businesses that also manufacture or distribute biologics (e.g., certain contract manufacturers or importers).
What you must do
No immediate action for pure cosmetics businesses. If you handle biologics, review the proposed changes and consider submitting comments by the deadline.
Deadline
Comments due by September 4, 2026.
Never miss a change like this again
Aforeworn watches Cosmetics & Personal-Care (MoCRA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Cosmetics & Personal-Care (MoCRA)
- FDA Launches One-Day Inspectional Assessments to Strengthen and Expand Oversight
- FDA Grants Seventh Approval under the National Priority Voucher Pilot Program
- FDA Issues Guidance to Improve Collection of Pregnancy Safety Data for Drugs and Biologics
- FDA Expands AI Capabilities and Completes Data Platform Consolidation
- FDA Approves First Treatment for Chronic Hepatitis Delta Virus (HDV) Infection